Nombramientos del Consejo
30 de enero de 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition" o la "Compañía")
Nombramientos del Consejo
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the appointment of Stuart Gall and Philip Rodgers ("Nick") as independent non-executive Directors of the Company, both with effect from 1 February 2024.
As announced in the Trading Update this morning, the Company has seen revenue growth of 7% in 2023 and an adjusted operating profit in the second half in a difficult economic environment and is positioned to deliver further growth in the future. The appointments will strengthen the Board to support these growth plans by adding additional commercial, investor relations and financial expertise. The additions to the Board take the number of non-executive directors to five; providing strengthened governance and succession for possible future rotation of Board members.
Stuart Gall is CEO of Intelligent Ultrasound, an AIM-listed medical imaging company providing one of the world's leading 'classroom to clinic' ultrasound technologies. Previous appointments include joint founder and executive director of Fusion IP plc, an AIM listed university IP commercialisation company, before its purchase by IP Group plc for £103 million in 2014. Stuart has over 30 years' experience in both small company start-ups and public companies and previously worked at British Airways plc, The Promotions Partnership Limited, Anvil Limited and Toad plc (now Journeo plc).
Nick Rodgers is currently Chair of SEHTA, one of the largest health technology membership and networking organisations in the UK supporting businesses in the health technology sector. Until 2023 Nick was Chair of Destiny Pharma plc, a developer of novel anti-infective products and chair of ZPN Energy Limited, a developer of battery storage technologies and systems for the electric vehicle market. Previously, until 2016, Nick was chairman of Oxford BioMedica plc, a pioneer of gene and cell therapy and a leader in lentiviral vector research, development and bioprocessing.
Dr Steven Powell, Chairman of Cambridge Cognition, commented:
"On behalf of the Board, I am delighted to welcome Stuart and Nick to Cambridge Cognition. Their broad expertise and deep industry experience in the healthcare and technology sectors will be extremely valuable in the next stage of Cambridge Cognition's development now that we have integrated the two acquisitions made in 2022/23, which strengthen the Company's product offering and cement its leading market position. We look forward to benefitting from their insights as the Board continues to lead Cambridge Cognition to profitability and accelerate and execute the Company's growth plans."
Información adicional
The following details in relation to the appointments of Stuart Gall and Nick Rodgers as directors of the Company are disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules for companies:
Stuart Arthur Gall (aged 61 years) holds or has held the following directorships or partnerships in the last five years:
Current | Últimos 5 años |
Intelligent Ultrasound Limited | DEMASQ Limited |
Grupo de ultrasonido inteligente plc | I2LResearch Ltd |
Medaphor International Limited | |
Medaphor Limited | |
Inventive Medical Limited | |
IML Finance Ltd | |
Intelligent Ultrasound North America Inc |
Stuart was also a director of Abcellute Limited and Abcellute Tissue Bank Limited at the time that both companies entered into a creditors liquidation on 10 October 2012. Abcellute Limited was subsequently dissolved on 17 September 2016 and Abcellute Tissue Bank Limited was dissolved on 10 March 2016.
Philip Nicholas 'Nick' Rodgers (aged 65 years) holds or has held the following directorships or partnerships in the last five years:
Current | Últimos 5 años |
Science and Engineering Health Technologies Alliance Limited | Alcuris Ltd |
SEHTA Enterprises Limited | Destino Pharma plc |
Nick Rodgers Financial Limited | Interactive Me Ltd |
Productiv Limited | Powerme Leasing Ltd |
Productiv Property Limited | |
Productiv Technology Limited | |
The Proving Factory Limited | |
Zapme Limited | |
ZPN Energy Limited |
Productiv Limited, a company which Nick Rodgers is a director of, entered into a creditors voluntary liquidation on 21 November 2022. The Company is currently still in liquidation.
Save as disclosed above, there is no further information to be disclosed in relation to appointments of Stuart Gall or Nick Rodgers pursuant to AIM Rule 17 or Schedule Two, paragraph (g) of the AIM Rules for Companies.
La Compañía considera que la información contenida en este anuncio constituye información privilegiada estipulada en el Reglamento de abuso de mercado (UE) No. 596/2014, ya que forma parte de la legislación nacional del Reino Unido en virtud de la Ley de (Retirada) de la Unión Europea de 2018. la publicación de este anuncio a través del Servicio de Información Reglamentaria, esta información privilegiada ahora se considera de dominio público.
Consultas
Cambridge Cognition Holdings plc | |
Matthew Stork, director ejecutivo Stephen Symonds, director financiero | Tel: 01223 810 700 |
Panmure Gordon (UK) Ltd (NOMAD and Joint Broker) Freddy Crossley/Emma Earl/Mark Rodgers Rupert Dearden
| Tel: 020 78862500 (Asesoramiento corporativo) (Corretaje corporativo) |
Dowgate Capital Limited (Articulación Broker) David Poutney/James Serjeant | Tel: 020 3903 7715 (Corretaje corporativo) |
hudson sandler (Relaciones Públicas y Relaciones Públicas financieras) Dan de Belder/Hattie Dreyfus | Tel: 020 7796 4133 |
Notas a los editores
Acerca de la cognición de Cambridge
Cambridge Cognition es una empresa de tecnología que desarrolla productos de salud digital para comprender, detectar y tratar mejor las afecciones que afectan la salud del cerebro. Los productos de software de la compañía evalúan la salud cognitiva en pacientes de todo el mundo para mejorar los resultados de los ensayos clínicos, identificar y estratificar a los pacientes de manera temprana y mejorar la eficiencia global en las industrias farmacéutica y de atención médica.
Para más información visite www.cambridgecognition.com
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.